On November 2, 2022 Wildflower Biopharma reported the National Institute of Health rewarded a grant this fall to the company (Press release, Wildflower Biopharma, NOV 2, 2020, View Source [SID1234632139]). The work/research is explained in the Grant Title: "Efficacy of a novel small-molecule splicing modulator in chronic lymphocytic leukemia (CLL)".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Wildflower Team is excited to announce that the Grant work will be performed at BioLabs San Diego and in collaboration with Huidong Shi at the Department of Biochemistry and Molecular Biology at Augusta University, Georgia.